# Molecular Basis of the Humoral Immune Response in Heparin-Induced Thrombocytopenia

> **NIH NIH R01** · VERSITI BLOOD HEALTH, INC. · 2022 · $582,999

## Abstract

Project Summary/Abstract
Title: Molecular basis of the humoral immune response in heparin-induced thrombocytopenia
Heparin induced thrombocytopenia (HIT) is the most common adverse drug reaction affecting blood cells.
Although heparin is an important anticoagulant widely used in many clinic settings, heparin exposure often
leads to production of antibodies (Abs) specific for conformational epitopes expressed by the platelet alpha
granule chemokine, platelet factor 4 (PF4) when it binds to heparin to form a complex (PF4/H). In some
patients, particularly after surgery, these Abs provoke HIT, characterized by thrombocytopenia and often life-
threatening arterial or venous thrombosis/thromboembolism. This complication is thought to result, at least in
part, from PF4-dependent Ab binding to platelets, monocytes and possibly other target cells, leading to cell
activation via Fc receptors and generation of procoagulant activity. The mechanisms by which heparin-induced
Abs cause thrombocytopenia and thrombosis are partially understood, but very little is known about the
molecular basis of the underlying immune response itself. One unique feature of HIT is that 25-50% of patients
exposed to heparin produce Abs that recognize PF4/H but only 0.1-1.0% experience the classical HIT
syndrome. Why some heparin-induced Ab are “benign” or “non-pathogenic” and others are “pathogenic”
cannot be accounted for on the basis of Ab potency alone. In this application, we propose to provide a
molecular explanation for why some heparin-induced Abs cause pathology whereas others that may recognize
PF4/H equally well fail to cause disease. Our studies will be facilitated by close collaboration with clinicians and
translational scientists engaged in research to improve understanding of HIT pathogenesis and improve
diagnosis and treatment of this condition.

## Key facts

- **NIH application ID:** 10491676
- **Project number:** 5R01HL148120-04
- **Recipient organization:** VERSITI BLOOD HEALTH, INC.
- **Principal Investigator:** Renren Wen
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $582,999
- **Award type:** 5
- **Project period:** 2019-06-01 → 2024-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10491676

## Citation

> US National Institutes of Health, RePORTER application 10491676, Molecular Basis of the Humoral Immune Response in Heparin-Induced Thrombocytopenia (5R01HL148120-04). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10491676. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*